Greenbrook TMS Inc., together with its subsidiaries, controls and operates a network of outpatient mental health services centers in the United States. Its centers specialize in the provision of transcranial magnetic stimulation (TMS) therapy, an FDA-cleared neurostimulation therapy for the treatment of major depressive disorder and other mental health disorders. The company also offers Spravato, an esketamine nasal spray; and other treatment modalities for the treatment of depression and related psychiatric services. Greenbrook TMS Inc. was founded in 2011 and is headquartered in Toronto, Canada. As of December 9, 2024, Greenbrook TMS Inc. operates as a subsidiary of Neuronetics, Inc.